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ABSTRACT The multidrug resistance profiles of Klebsiella pneumoniae carbapen-
emase (KPC) producers have led to increased clinical polymyxin use. Combina-
tion therapy with polymyxins may improve treatment outcomes, but it is uncer-
tain which combinations are most effective. Clinical successes with intravenous
minocycline-based combination treatments have been reported for infections
caused by carbapenemase-producing bacteria. The objective of this study was to
evaluate the in vitro activity of polymyxin B and minocycline combination ther-
apy against six KPC-2-producing K. pneumoniae isolates (minocycline MIC range,
2 to 32 mg/liter). Polymyxin B monotherapy (0.5, 1, 2, 4, and 16 mg/liter) re-
sulted in a rapid reduction of up to 6 log in bactericidal activity followed by re-
growth by 24 h. Minocycline monotherapy (1, 2, 4, 8, and 16 mg/liter) showed
no reduction of activity of 1.34 log against all isolates, although concentrations
of 8 and 16 mg/liter prolonged the time to regrowth. When the therapies were
used in combination, rapid bactericidal activity was followed by slower regrowth,
with synergy (60 of 120 combinations at 24 h, 19 of 120 combinations at 48 h)
and additivity (43 of 120 combinations at 24 h, 44 of 120 combinations at 48 h)
against all isolates. The extent of killing was greatest against the more suscepti-
ble polymyxin B isolates (MICs of 0.5 mg/liter) regardless of the minocycline
MIC. The pharmacodynamic activity of combined polymyxin B-minocycline ther-
apy against KPC-producing K. pneumoniae is dependent on polymyxin B suscep-
tibility. Further in vitro and animal studies must be performed to fully evaluate
the efficacy of this drug combination.
KEYWORDS polymyxin, minocycline, Klebsiella pneumoniae, KPC, MDR, antimicrobial
combinations, multidrug resistance
Klebsiella pneumoniae is a ubiquitous colonizer of the gastrointestinal tract and acommon cause of nosocomial pneumonia and of bloodstream and urinary tract
infections (1, 2). Drug-resistant K. pneumoniae infections are often treated with carbap-
enems, but the increasing dissemination of carbapenem-resistant strains has led to
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higher mortality rates and longer hospital stays for affected individuals (2–4). Since K.
pneumoniae carbapenemase (KPC) was first detected in 2001 in North Carolina, KPC-
producing Enterobacteriaceae have become endemic in the United States, Greece,
Israel, Italy, China, Brazil, Colombia, and Argentina (5–7). Monotherapy against KPC-
producing bacteria has higher treatment failure rates than combination therapy (8),
with the development of resistance likely to be partially responsible. Cases of colistin
(polymyxin E)-resistant carbapenemase-producing Enterobacteriaceae strains arising
from suboptimal exposure to colistin have been reported in some countries (9, 10).
Further, the recent emergence of the first plasmid-mediated polymyxin resistance
mechanism in Enterobacteriaceae is indicative of the need for combination therapy
against these bacteria (9, 11–13).
Although minocycline is not commonly used for the treatment of KPC-producing K.
pneumoniae infections, there are reports of clinical success with intravenous
minocycline-based combinations against carbapenemase-producing K. pneumoniae
and Acinetobacter baumannii infections. Further research into the efficacy of minocy-
cline and polymyxin combination regimens is therefore warranted (14–16). Minocycline
inhibits bacterial protein synthesis and has favorable tissue penetrability due to its
lipophilicity (16). Minocycline combined with colistin is synergistic against multidrug-
resistant (MDR) A. baumannii (17–19) based on the hypothesis that polymyxin disrupts
outer membrane integrity to raise intracellular concentrations of minocycline in Gram-
negative bacteria (20, 21). The objective of this study was to evaluate the rate and
extent of killing activity of polymyxin B and minocycline alone and in combination
against KPC-2-producing K. pneumoniae isolates using static in vitro time-kill studies.
RESULTS
Characterization of clinical isolates revealed KPC-2 production in all isolates. No
additional -lactamases were detected. The mgrB gene was functional in all polymyxin
B-sensitive isolates and was truncated in the polymyxin B-resistant BRKP57 isolate.
None of the isolates contained the tet(B) resistance determinant.
Monotherapy. Log changes in CFU per milliliter at 4, 24, and 48 h compared to the
starting inoculum at 0 h for both polymyxin B monotherapy and minocycline mono-
therapy are shown in Table 1. Polymyxin B monotherapy displayed concentration-
dependent rapid bactericidal activity for all concentrations that peaked by 4 h against
the polymyxin B-sensitive BRKP62, BRKP07, BRKP21, BRKP25, and BRKP27 isolates (Table
1; see also Fig. S1 in the supplemental material). However, bactericidal activity was not
sustained beyond 8 h, and regrowth similar to the growth control results occurred
beyond 24 h at polymyxin B concentrations of 4 mg/liter. The highest polymyxin B
concentration evaluated (16 mg/liter) demonstrated a lower rate of regrowth similar to
the growth control results, with a slight delay against BRKP62, BRKP21, and BRKP25 (Fig.
S1a, c, and d). Against the polymyxin B-resistant BRKP57 isolate, polymyxin B at 16
mg/liter showed minimal activity, resulting in a 1 log10 reduction followed by
regrowth.
Minocycline monotherapy did not result in bactericidal activity against any of the
isolates at any of the minocycline concentrations (Table 1). All monotherapy concen-
trations eventually resulted in growth similar to the growth control results by 48 h,
although the rate of regrowth decreased with increasing minocycline concentrations
(Fig. S2). The results seen with minocycline concentrations of 1, 2, and 4 mg/liter were
comparable to the growth control results regardless of the minocycline susceptibility of
the isolate. Minocycline at 8 mg/liter resulted in a 1 log10 reduction at 4 h against all
isolates (Table 1), with regrowth observed by 24 h in the minocycline-susceptible
(BRKP07, BRKP62, and BRKP57) isolates and by 8 h in the minocycline-resistant (BRKP27,
BRKP21, and BRKP25) isolates. Minocycline at 16 mg/liter performed slightly better,
resulting in a maximal reduction of 1.34 log10 at 4 h followed by regrowth in all isolates
by 28 h.
Combination therapy. Log changes in CFU per milliliter at 4, 24, and 48 h
compared to the starting inoculum that resulted from the use of minocycline and
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polymyxin B in combination are shown in Table 2. Time-kill profiles for polymyxin B in
combination with minocycline against four isolates with various levels of polymyxin B
susceptibility (for BRKP62, polymyxin B MIC  0.5 mg/liter; for BRKP25, polymyxin B
MIC  0.5 mg/liter; for BRKP27, polymyxin B MIC  1 mg/liter; for BRKP57, polymyxin
B MIC  64 mg/liter) are shown in Fig. 1.
Against BRKP62, an isolate susceptible to both polymyxin B and minocycline (poly-
myxin B MIC, 0.5 mg/liter; minocycline MIC, 4 mg/liter), polymyxin at 0.5 and 1
mg/liter in combination with all minocycline concentrations resulted in a 2 log
reduction by 8 h followed by regrowth similar to the growth control results at 48 h.
Polymyxin B at 2 mg/liter in combination with minocycline at 1, 2, and 4 mg/liter
resulted in bactericidal activity by 4 h followed by regrowth at up to 107 CFU/ml at 48 h
(Fig. 1a, e, and i and Table 2). Polymyxin B at 2 and 4 mg/liter combined with
minocycline at 8 and 16 mg/liter resulted in undetectable levels of isolate BRKP62 by
6 h that were sustained up to 48 h (Fig. 1m and q and Table 2).
Against the polymyxin B-sensitive and minocycline-resistant BRKP25 isolate (poly-
myxin B MIC, 0.5 mg/liter; minocycline MIC, 32 mg/liter), polymyxin B concentrations of
2 mg/liter in combination with all minocycline concentrations were bactericidal by 4
h followed by regrowth beyond 24 h (Fig. 1b, f, j, n, and r). Surprisingly, the same
activity was seen against BRKP07 and BRKP21, which also have a polymyxin B MIC of 0.5
mg/liter but different minocycline MICs of 2 and 16 mg/liter, respectively (Table 2; see
also Fig. S3). Increasing minocycline concentrations against these isolates failed to
improve the extent of killing regardless of the minocycline MIC.
Against BRKP27 (polymyxin B MIC, 1.0 mg/liter; minocycline MIC, 8 mg/liter), poly-
myxin B and minocycline together at all concentrations resulted in a 2 log reduction
by 8 h followed by regrowth by 48 h (Fig. 1c, g, k, o, and s).
The combination demonstrated minimal activity against the highly polymyxin
B-resistant and minocycline-sensitive BRKP57 isolate (polymyxin B MIC, 64 mg/liter;
minocycline MIC, 4 mg/liter) (Fig. 1d, h, l, p, and t). Polymyxin B at all concentrations
combined with minocycline at 16 mg/liter resulted in a 1 log reduction at 24 h
TABLE 1 The change in log10 CFU per milliliter at 4, 24, and 48 h during time-kill experiments with monotherapy with polymyxin B or
minocycline against an inoculum of 106 CFU/ml of KPC-producing K. pneumoniae clinical isolatesa
Clinical
isolate Time (h)
Change in log10 no. of CFU/ml with:
Control
PMB (mg/liter) MIN (mg/liter)
0.5 1 2 4 16 1 2 4 8 16
BRKP62 4 1.97 3.32 4.58 4.84 6.11 6.25 2.19 1.41 0.12 0.15 0.30
24 2.81 2.90 2.61 2.74 2.51 3.04 3.27 3.03 2.48 2.38 1.06
48 2.95 3.09 2.90 3.10 3.07 2.06 3.20 3.37 3.18 3.11 3.14
BRKP07 4 2.12 3.49 2.77 2.70 2.60 6.01 1.71 0.18 0.79 0.66 0.55
24 2.98 3.00 3.08 3.06 2.97 2.20 2.88 2.90 2.78 2.70 1.38
48 3.21 3.16 3.21 3.32 3.21 3.19 2.77 2.91 2.84 2.79 2.91
BRKP21 4 2.35 3.48 3.44 3.66 6.21 6.00 2.29 0.70 0.30 0.06 0.87
24 2.97 3.03 2.71 2.83 2.89 1.20 3.00 3.04 2.91 2.91 2.69
48 2.97 3.24 2.88 2.89 3.05 3.12 2.95 3.04 2.86 3.12 3.19
BRKP25 4 2.42 4.00 4.26 4.18 4.62 5.87 2.55 2.34 0.80 0.01 0.20
24 3.05 3.15 3.07 1.27 2.91 4.09 3.07 2.24 2.14 2.26 0.10
48 3.08 3.28 3.48 3.32 3.41 2.09 3.21 2.73 2.56 2.58 2.73
BRKP27 4 1.93 3.07 1.99 2.29 2.56 4.49 1.17 1.27 0.78 0.78 1.34
24 2.62 2.83 2.76 2.00 2.47 2.89 3.07 2.91 2.77 2.99 2.75
48 2.69 2.65 2.89 2.62 2.29 2.61 2.99 3.00 2.99 3.05 2.55
BRKP57 4 2.07 1.44 1.52 1.13 0.59 0.48 1.74 0.83 0.50 0.00 0.35
24 3.05 2.98 3.09 3.16 3.09 3.15 3.02 2.54 2.64 2.11 0.34
48 3.31 3.16 3.20 3.40 3.37 3.19 3.15 2.73 3.06 2.97 2.59
aBactericidal activity (3 log10 CFU/ml reduction compared to the initial inoculum) is shown in bold. PMB, polymyxin B; MIN, minocycline.
Polymyxin Minocycline for KPC-Producing K. pneumoniae Antimicrobial Agents and Chemotherapy
July 2017 Volume 61 Issue 7 e00073-17 aac.asm.org 3
TA
B
LE
2
Th
e
ch
an
ge
in
lo
g 1
0
C
FU
p
er
m
ill
ili
te
r
at
4,
24
,a
nd
48
h
du
rin
g
tim
e-
ki
ll
ex
p
er
im
en
ts
w
ith
p
ol
ym
yx
in
B
in
co
m
b
in
at
io
n
w
ith
m
in
oc
yc
lin
e
ag
ai
ns
t
an
in
oc
ul
um
of

10
6
C
FU
/
m
l
of
KP
C
-p
ro
du
ci
ng
K.
pn
eu
m
on
ia
e
cl
in
ic
al
is
ol
at
es
a
C
lin
ic
al
is
ol
at
e
Ti
m
e
(h
)
C
on
tr
ol
C
h
an
g
e
in
lo
g
1
0
n
o.
of
C
FU
/m
l
w
it
h
:
PM
B
at
0.
5
m
g
/l
it
er
an
d
a
M
IN
co
n
cn
(m
g
/l
it
er
)
of
:
PM
B
at
1.
0
m
g
/l
it
er
an
d
a
M
IN
co
n
cn
(m
g
/l
it
er
)
of
:
PM
B
at
2.
0
m
g
/l
it
er
an
d
a
M
IN
co
n
cn
(m
g
/l
it
er
)
of
:
PM
B
at
4.
0
m
g
/l
it
er
an
d
a
M
IN
co
n
cn
(m
g
/l
it
er
)
of
:
1
2
4
8
16
1
2
4
8
16
1
2
4
8
16
1
2
4
8
16
BR
KP
62
4
1.
97

2.
62

2.
26

1.
77

0.
44

0.
56

2.
72

2.
93

2.
88

1.
41

1.
41

3.
40

3.
85

2.
23

3.
34

2.
92

2.
92

2.
81

3.
77

4.
84

3.
91
24
2.
81
1.
21
1.
26
1.
11
0.
89

1.
41
0.
79
1.
12
1.
09

0.
37

1.
75
0.
03

0.
79

3.
53

6.
20

6.
20

0.
60

2.
47

3.
47

6.
14

6.
16
48
2.
95
3.
14
2.
73
2.
99
2.
68
2.
59
2.
88
2.
66
2.
97
1.
92
0.
92
1.
23
0.
89
0.
73

6.
20

6.
20
1.
31
0.
67
0.
83

4.
06

6.
16
BR
KP
07
4
2.
37

3.
07

2.
47

3.
13

3.
14

1.
55

3.
68

2.
99

2.
76

4.
32

4.
17

4.
15

4.
39

3.
55

4.
33

4.
82

4.
92

4.
45

4.
38

4.
93

6.
13
24
2.
98
0.
92
0.
81
0.
41

0.
67
0.
76
0.
64
0.
90
0.
76

1.
17

0.
80

1.
89

2.
01

6.
25

0.
93

1.
03

2.
21

2.
25

3.
28

1.
89

0.
78
48
3.
21
2.
95
2.
99
2.
91
2.
90
2.
56
3.
08
3.
02
2.
78
1.
27
0.
78
2.
95
1.
37
0.
96
0.
87
1.
03
2.
87
1.
30
1.
15
0.
81
1.
13
BR
KP
21
4
2.
35

1.
79

3.
04

1.
67

2.
55

0.
58

2.
61

2.
16

2.
22

1.
25

1.
19

3.
20

3.
83

4.
38

4.
41

4.
24

3.
68

4.
05

3.
61

4.
03

3.
33
24
2.
97
2.
97
1.
09
1.
37
1.
43
1.
19
2.
24
0.
47
1.
02
1.
00
0.
83
2.
81
2.
75
0.
84
0.
74
0.
82
0.
32

0.
04

0.
52

0.
91

1.
13
48
2.
97
3.
46
3.
05
3.
17
2.
98
3.
02
3.
49
3.
02
3.
02
2.
89
0.
90
2.
94
2.
92
2.
68
0.
99
0.
73
2.
36
1.
44
1.
22
1.
11

0.
54
BR
KP
25
4
2.
50

2.
18

2.
21

1.
90

1.
55

1.
18

2.
86

3.
54

2.
72

3.
90

2.
96

3.
55

3.
36

3.
04

2.
74

3.
74

4.
21

6.
26

4.
57

4.
86

4.
78
24
3.
05
1.
76
1.
09
1.
38
0.
88
1.
01
1.
45
1.
25
1.
12
1.
21
0.
85
0.
75
0.
86
1.
08

0.
48

0.
40

1.
73

1.
42

0.
68

0.
81

2.
56
48
3.
08
3.
20
3.
03
3.
06
3.
22
2.
84
3.
18
3.
08
2.
99
3.
47
1.
10
2.
88
1.
41
1.
38
1.
03
1.
05
2.
66
2.
24
0.
63

0.
31

0.
36
BR
KP
27
4
2.
24

2.
03

1.
59

1.
04

0.
86

1.
70

2.
11

2.
08

1.
46

1.
43

0.
95

2.
31

2.
33

1.
69

1.
54

1.
17

2.
60

2.
49

2.
69

1.
66

1.
55
24
2.
62
2.
73
1.
22
1.
02

0.
26

0.
25
0.
93
0.
84
0.
49
0.
88

2.
85
0.
77
0.
66
0.
53

0.
46

3.
44
0.
44
0.
16

1.
80

1.
69

3.
44
48
2.
69
3.
22
2.
81
2.
62
1.
07
1.
19
3.
00
2.
42
2.
77
2.
06

1.
55
1.
01
0.
95
1.
18
0.
92

1.
61
2.
82
1.
07
1.
01

1.
11

0.
79
BR
KP
57
4
2.
07
0.
07

0.
21

0.
15
0.
11
0.
02

0.
07
0.
00

0.
21

0.
12

0.
21

0.
06

0.
15

0.
10

0.
04

0.
23
0.
02

0.
13

0.
14

0.
17

0.
17
24
3.
05
1.
46
0.
86
0.
54
0.
86

1.
13
1.
02
1.
20
0.
95
0.
68

1.
43
0.
77
0.
64
0.
87
0.
31

1.
14
0.
10

0.
72

0.
98

1.
05

1.
18
48
3.
31
3.
10
2.
70
3.
24
2.
50
0.
86
2.
84
2.
94
2.
57
0.
58
0.
42
2.
52
1.
26
1.
03
0.
85

0.
38
0.
83
0.
79
0.
98
0.
60

0.
54
a
Ba
ct
er
ic
id
al
ac
tiv
ity
(
3
lo
g 1
0
C
FU
/m
l
re
du
ct
io
n
co
m
p
ar
ed
to
th
e
in
iti
al
in
oc
ul
um
)
is
in
di
ca
te
d
in
b
ol
d.
A
dd
iti
vi
ty
is
de
fin
ed
as
a
re
du
ct
io
n
of
b
et
w
ee
n
1
an
d
2
lo
g 1
0
C
FU
/m
l
an
d
sy
ne
rg
y
is
de
fin
ed
as
a
re
du
ct
io
n
of

2
lo
g 1
0
C
FU
/m
l
ca
us
ed
b
y
th
e
co
m
b
in
at
io
n
co
m
p
ar
ed
to
th
e
re
su
lt
s
se
en
w
ith
th
e
m
os
t
ac
tiv
e
si
ng
le
ag
en
t
in
th
e
co
m
b
in
at
io
n.
A
dd
iti
vi
ty
is
hi
gh
lig
ht
ed
w
ith
lig
ht
gr
ay
sh
ad
in
g
an
d
sy
ne
rg
y
w
ith
da
rk
gr
ay
sh
ad
in
g.
PM
B,
p
ol
ym
yx
in
B;
M
IN
,m
in
oc
yc
lin
e.
Huang et al. Antimicrobial Agents and Chemotherapy
July 2017 Volume 61 Issue 7 e00073-17 aac.asm.org 4
FIG 1 Time-kill curves of polymyxin B (PMB) at 0.5, 1, 2, and 4 mg/liter in combination with minocycline (MIN) at 1, 2, 4, 8, and 16 mg/liter against an inoculum
of 106 CFU/ml of the following KPC-producing K. pneumoniae clinical isolates: (i) BRKP62 (polymyxin B MIC, 0.5 mg/liter; minocycline MIC, 4 mg/liter), (ii)
BRKP25 (polymyxin B MIC, 0.5 mg/liter; minocycline MIC, 32 mg/liter), (iii) BRKP27 (polymyxin B MIC, 1 mg/liter; minocycline MIC, 8 mg/liter), and (iv) BRKP57
(polymyxin B MIC, 64 mg/liter; minocycline MIC, 4 mg/liter).
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followed by regrowth by 48 h. Across all isolates, the pharmacodynamic activity
decreased with increasing polymyxin B MIC regardless of the level of minocycline
susceptibility (Fig. 1).
Combination therapy did not result in synergy before 4 h except for BRKP07, as the
addition of minocycline did not increase the extent of early bactericidal activity seen
with polymyxin B alone (Table 2). At 24 h, 60 of 120 (50%) combinations were
considered synergistic and 43 of 120 (36%) combinations were considered additive. At
48 h, 19 of 120 (16%) combinations were synergistic and 44 of 120 (37%) were additive.
A striking similarity between all isolates was that combinations with polymyxin B at 4
mg/liter were synergistic.
DISCUSSION
Here we evaluated polymyxin B and minocycline as monotherapy and in combina-
tion against six clinical K. pneumoniae isolates with various levels of susceptibilities to
each antibiotic. Polymyxin B monotherapy resulted in rapid bactericidal activity fol-
lowed by regrowth by 24 h. While minocycline monotherapy at high concentrations
increased the time to regrowth of all isolates, no bactericidal activity was observed. In
combination with polymyxin B, the rapid bactericidal killing was followed by slower
regrowth, as evidenced by synergy up to 48 h against all isolates. The extent of killing
was greatest against the more susceptible polymyxin B isolates, as early bactericidal
activity was seen when polymyxin B MICs were 0.5 mg/liter regardless of the
minocycline MIC. Bactericidal activity was sustained at 48 h only against the most
polymyxin B-susceptible isolate (MIC, 0.5). Killing activity was attenuated with in-
creasing polymyxin B MIC. In addition, bactericidal activity was observed at polymyxin
B concentrations of 2 mg/liter, and synergy was observed against all isolates at the
high concentration of 4 mg/liter. These findings further confirm that the pharmacody-
namic activity of this combination is dependent on the level of polymyxin B suscepti-
bility.
Previous studies have evaluated polymyxin (polymyxin B or colistin) in combination
with minocycline against A. baumannii in both in vitro and in vivo models of infection
with favorable results (17–19). Bowers et al. (20) determined that subinhibitory con-
centrations of polymyxin B (0.5 mg/liter) could increase intracellular minocycline con-
centrations (2 and 8 mg/liter) and enhance minocycline’s activity in static time-kill
experiments against three clinical isolates and one laboratory isolate (20) with poly-
myxin B MICs of 2 mg/liter and minocycline MICs ranging between 0.25 and 16
mg/liter. Zhang et al. (21) determined that the combination significantly reduced the
MICs (polymyxin B, 0.25 to 4 mg/liter; minocycline, 0.25 to 8 mg/liter) against 25
resistant A. baumannii strains compared to the MIC for either polymyxin B (1 to 8
mg/liter) or minocycline (4 to 16 mg/liter) used as monotherapy (21). They also
determined the synergy of the combination using the fractional inhibitory concentra-
tion index (FICI). Yang et al. (22) tested the colistin and minocycline combination
against four minocycline-resistant and colistin-sensitive isolates (minocycline MICs of 16
and 32 mg/liter; colistin MIC, 0.5 mg/liter) and revealed similar FICI results using a
checkerboard synergy assay (22). Time-kill experiments in the same study using mino-
cycline at 4 and 16 mg/liter in combination with colistin at 0.5 mg/liter showed synergy
in all four isolates. Our study revealed similar findings for KPC-producing K. pneumoniae,
as polymyxin B and minocycline were synergistic. However, bactericidal activity and
synergy were more apparent when polymyxin B concentrations were 2 mg/liter
against polymyxin-susceptible isolates.
Several hypotheses may explain the efficacy of this combination (20, 22, 23).
Polymyxin B might increase membrane permeability and intracellular minocycline
concentrations. Polymyxins competitively displace cations from the phosphate groups
of lipopolysaccharide and phospholipids of lipid A in the outer membrane of Gram-
negative bacteria, leading to leakage of intracellular contents and eventual cell death.
Polymyxin B may also alter the function of efflux pumps in bacterial membranes that
are responsible for minocycline resistance (20). Tetracycline resistance is often due to
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the presence of various tet genes that code for upregulation of efflux pumps or
ribosomal protection. Unlike that of the other tetracyclines, minocycline resistance is
primarily attributable to the tet(B) gene, which upregulates efflux pumps (24). Our
results are consistent with both hypotheses, as the pharmacodynamic activity was
greatest against the more polymyxin-susceptible strains and at higher polymyxin B
concentrations regardless of minocycline susceptibility. However, resistance to poly-
myxin B is another growing concern. Dysfunction of the mgrB gene has been found to
upregulate the PhoP/PhoQ system, which reduces the negative charge of lipid A and
subsequently the affinity of polymyxin B (25).
To our knowledge, this is the first report to evaluate polymyxin B and minocycline
against KPC-producing K. pneumoniae. Further, we evaluated this combination against
clinical isolates with a broad range of polymyxin B and minocycline susceptibilities. The
combination performed better than monotherapy against all isolates by prolonging the
time to regrowth to control levels from 24 h to 48 h. Bactericidal activity was observed
against all polymyxin B-sensitive isolates with MICs of 0.5 mg/liter at clinically
achievable concentrations. As such, this combination might be a viable treatment
option against infections with such isolates. Although synergy was present, this com-
bination did not demonstrate sustained bactericidal activity against these isolates past
8 h at clinically achievable concentrations. We also showed that the combination did
not perform well against the highly polymyxin B-resistant BRKP57 isolate. Triple com-
binations, although infrequently used in the United States, may be necessary for
prolonged sustained activity to treat infections due to highly resistant K. pneumoniae
isolates. Previous studies have suggested a clinical and microbiological benefit to
three-drug combinations (7, 26). Moreover, adding an additional drug such as a
carbapenem or fosfomycin to the polymyxin B and minocycline combination may
increase efficacy against KPC-producing K. pneumoniae by increasing the log kill rate of
polymyxin B with minocycline to theoretically slow any regrowth. Additional studies to
assess such combinations are warranted.
This study had limitations. Antibiotic concentrations in time-kill experiments are
inherently constant and do not fully simulate the pharmacokinetics of antibiotic drug
regimens in the clinical setting. Therefore, these findings may not accurately reflect the
activity of polymyxin B and minocycline in vivo in the presence of drug metabolism and
elimination and/or in the presence of an active immune system. The pharmacodynamic
activity in response to humanized regimens needs to be evaluated, perhaps first
employing in vivo infection models, to further our knowledge and enable translation of
these combinations to the clinic.
As KPC-producing K. pneumoniae strains continue to spread and treatment options
become more limited, it is important to determine which combinations of existing
antibiotics are most effective and to prevent the emergence of further resistance. In this
study, polymyxin B and minocycline showed synergistic activity at clinically relevant
concentrations, although sustained activity was not achieved beyond 24 h and the
mechanism has yet to be fully elucidated. Further in vitro and animal studies should be
performed to evaluate the efficacy of this drug combination.
MATERIALS AND METHODS
Bacterial isolates, susceptibilities, and characterization. Six clinical K. pneumoniae strains (BRKP62
[polymyxin B MIC, 0.5 mg/liter; minocycline MIC, 4 mg/liter], BRKP07 [polymyxin B MIC, 0.5 mg/liter;
minocycline MIC, 2 mg/liter], BRKP21 [polymyxin B MIC, 0.5 mg/liter; minocycline MIC, 16 mg/liter],
BRKP25 [polymyxin B MIC, 0.5 mg/liter; minocycline MIC, 32 mg/liter], BRKP27 [polymyxin B MIC, 1
mg/liter; minocycline MIC, 8 mg/liter], and BRKP57 [polymyxin B MIC, 64 mg/liter; minocycline MIC, 4
mg/liter]) were obtained from the Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, during KPC
outbreaks between June 2009 and June 2013 (27). MICs were determined in triplicate using broth
microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines (28). Genomic
DNA was isolated from bacterial isolates using a DNA isolation kit (E.Z.N.A. bacterial DNA kit; Omega
Biotek, Norcross, GA). PCR analyses to evaluate the presence of seven different -lactamases belonging
to Ambler class A (GES and KPC), B (NDM, VIM, and IMP), and D (OXA-48 and OXA-40) (29) and of mgrB
(25) and tet(B) (30) were carried out using specific primers (see Table S1 in the supplemental material)
commercially synthesized by IDT (Integrated DNA Technologies, Inc., Coralville, IA). Q5 Hi-Fidelity Taq
DNA polymerase (NEB, Ipswich, MA) was used in PCRs. The PCR product sequencing was performed at
Polymyxin Minocycline for KPC-Producing K. pneumoniae Antimicrobial Agents and Chemotherapy
July 2017 Volume 61 Issue 7 e00073-17 aac.asm.org 7
the sequencing facility at Roswell Park Cancer Institute, Buffalo, NY. The NCBI website (www.ncbi.nlm
.nih.gov) was used for nucleotide and deduced protein sequence analysis. The insertion sequence (IS)
was analyzed using the IS finder website (https://www-is.biotoul.fr/). All isolates were stored at 80°C
and subcultured on Mueller-Hinton agar (MHA) 1 day prior to each experiment.
Antibiotics and media. Stock solutions of polymyxin B (Sigma-Aldrich, USA; catalog no. WXBB4470V)
and minocycline (Sigma-Aldrich, USA; catalog no. WXBB4793V) were prepared in water and filter
sterilized through 0.20-m-pore-size syringe filters (Corning Inc., Corning, NY) immediately prior to each
experiment. Susceptibility testing and static time-kill studies were performed using cation-adjusted (25.0
mg/liter Ca2 and 12.5 mg/liter Mg2) Mueller-Hinton broth (CAMHB) (Becton, Dickinson and Company,
Sparks, MD).
Time-kill studies. The bacterial killing activity of polymyxin B and minocycline as monotherapies and
in combination was evaluated against the six isolates by performing time-kill experiments over 48 h
using methods previously described (26). Polymyxin B concentrations of 0.5, 1, 2, 4, and 16 mg/liter and
minocycline concentrations of 1, 2, 4, 8, and 16 mg/liter were evaluated as monotherapy. A 4-by-5
concentration matrix of polymyxin B (0.5, 1, 2, and 4 mg/liter) in combination with minocycline (1, 2, 4,
8, and 16 mg/liter) and a growth control were also evaluated. The range of concentrations selected
included clinically achievable unbound plasma concentrations and supratherapeutic concentrations to
evaluate any potential benefits of intensive dosing. Minocycline dosed as a 200-mg intravenous infusion
over 30 to 60 min yields maximum concentrations of 3 to 8.75 mg/liter, and the steady-state plasma
concentrations following infusion of 100 mg of minocycline every 12 h range between 1 and 4 mg/liter
(31–33). The average steady-state plasma concentration of polymyxin B is reported as approximately 2.79
mg/liter for doses ranging from 0.45 to 3.38 mg/kg of body weight/day (34). Levels of protein binding
for minocycline and polymyxin B are 76% and 58%, respectively.
Subcultured bacterial isolates were added to CAMHB to produce a bacterial suspension with an initial
inoculum of 106 CFU/ml. The antibiotic(s) was added to the bacterial suspension in the logarithmic-
growth phase at 37°C. Samples were obtained at 0, 1, 2, 4, 6, 8, 24, 28, 32, and 48 h for bacterial
quantification. A ProtoCOL automated colony counter (Synbiosis, Cambridge, United Kingdom) was used
to quantify bacteria after 24 h of incubation at 37°C. The limit of quantification was 100 CFU/ml.
Pharmacodynamic analysis. The evaluation of the pharmacodynamic effect (E) of the individual and
combination therapies was performed according to the change in log10 CFU per milliliter at an early time
point of 4 h and at later time points of 24 and 48 h compared to the change in log10 CFU per milliliter
at baseline (0 h) according to the following equation:
E  log10
CFU(4, 24, or 48 h)
CFU(0 h)
Bactericidal activity was defined as a 3 log10 CFU/ml reduction from baseline. Synergy was defined
as a 2 log10 CFU/ml reduction and additivity as a 1 to 2 log10 reduction in CFU/ml caused by the
combination of polymyxin B and minocycline compared to the most active single agent in the
combination.
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